Theriva™ Biologics to Participate in the BIO-Europe Conference

Rhea-AI Summary

Theriva Biologics will provide a corporate update and participate in one-on-one meetings at the BIO-Europe Conference in Munich from November 6-8, 2023. The presentation is scheduled for Tuesday, November 7, 2023, at 11:15am CET.

ROCKVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update and participate in one-on-one meetings at the BIO-Europe Conference, to be held in Munich from November 6-8, 2023.

BIO-Europe Conference
Format: Corporate presentation and one-on-one meetings
Presentation Date: Tuesday, November 7, 2023
Presentation Time: 11:15am CET

About Theriva™ Biologics, Inc.

Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s wholly-owned Spanish subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. In addition to VCN-01, the Company’s clinical-stage candidates include: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients); and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.

For further information, please contact:
Investor Relations:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com 
917-680-5608
Source: Theriva Biologics, Inc.

FAQ

What is the name of the company providing the corporate update at the BIO-Europe Conference?

The company providing the corporate update is Theriva Biologics.

When and where will the BIO-Europe Conference take place?

The BIO-Europe Conference will take place in Munich from November 6-8, 2023.

When is the corporate presentation scheduled?

The corporate presentation is scheduled for Tuesday, November 7, 2023, at 11:15am CET.